Targeting neuropilin-1 in human leukemia and lymphoma

Katja Karjalainen, Diana E. Jaalouk, Carlos E. Bueso-Ramos, Amado J. Zurita, Akihiko Kuniyasu, Bedrich L. Eckhardt, Frank C. Marini, Benjamin Lichtiger, Susan O'Brien, Hagop M. Kantarjian, Jorge E. Cortes, Erkki Koivunen, Wadih Arap, Renata Pasqualini

Research output: Contribution to journalArticle

Abstract

Targeted drug delivery offers an opportunity for the development of safer and more effective therapies for the treatment of cancer. In this study, we sought to identify short, cell-internalizing peptide ligands that could serve as directive agents for specific drug delivery in hematologic malignancies. By screening of human leukemia cells with a combinatorial phage display peptide library, we isolated a peptide motif, sequence Phe-Phe/Tyr-Any-Leu-Arg-Ser (FF/YXLRS), which bound to different leukemia cell lines and to patient-derived bone marrow samples. The motif was internalized through a receptor-mediated pathway, and we next identified the corresponding receptor as the transmembrane glycoprotein neuropilin-1 (NRP-1). Moreover, we observed a potent anti-leukemia cell effect when the targeting motif was synthesized in tandem to the pro-apoptotic sequence D(KLAKLAK)2. Finally, our results confirmed increased expression of NRP-1 in representative human leukemia and lymphoma cell lines and in a panel of bone marrow specimens obtained from patients with acute lymphoblastic leukemia or acute myelogenous leukemia compared with normal bone marrow. These results indicate that NRP-1 could potentially be used as a target for liganddirected therapy in human leukemias and lymphomas and that the prototype CGFYWLRSC-GG- D(KLAKLAK)2 is a promising drug candidate in this setting.

Original languageEnglish (US)
Pages (from-to)920-927
Number of pages8
JournalBlood
Volume117
Issue number3
DOIs
StatePublished - Jan 20 2011
Externally publishedYes

Fingerprint

Neuropilin-1
Lymphoma
Bone
Leukemia
Cells
Bone Marrow
Peptide Library
Peptides
phenylalanylphenylalanine
Drug delivery
Pharmaceutical Preparations
Glycoproteins
Screening
Cell Line
Ligands
Hematologic Neoplasms
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Acute Myeloid Leukemia
Therapeutics
KLA peptide

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Karjalainen, K., Jaalouk, D. E., Bueso-Ramos, C. E., Zurita, A. J., Kuniyasu, A., Eckhardt, B. L., ... Pasqualini, R. (2011). Targeting neuropilin-1 in human leukemia and lymphoma. Blood, 117(3), 920-927. https://doi.org/10.1182/blood-2010-05-282921

Targeting neuropilin-1 in human leukemia and lymphoma. / Karjalainen, Katja; Jaalouk, Diana E.; Bueso-Ramos, Carlos E.; Zurita, Amado J.; Kuniyasu, Akihiko; Eckhardt, Bedrich L.; Marini, Frank C.; Lichtiger, Benjamin; O'Brien, Susan; Kantarjian, Hagop M.; Cortes, Jorge E.; Koivunen, Erkki; Arap, Wadih; Pasqualini, Renata.

In: Blood, Vol. 117, No. 3, 20.01.2011, p. 920-927.

Research output: Contribution to journalArticle

Karjalainen, K, Jaalouk, DE, Bueso-Ramos, CE, Zurita, AJ, Kuniyasu, A, Eckhardt, BL, Marini, FC, Lichtiger, B, O'Brien, S, Kantarjian, HM, Cortes, JE, Koivunen, E, Arap, W & Pasqualini, R 2011, 'Targeting neuropilin-1 in human leukemia and lymphoma', Blood, vol. 117, no. 3, pp. 920-927. https://doi.org/10.1182/blood-2010-05-282921
Karjalainen K, Jaalouk DE, Bueso-Ramos CE, Zurita AJ, Kuniyasu A, Eckhardt BL et al. Targeting neuropilin-1 in human leukemia and lymphoma. Blood. 2011 Jan 20;117(3):920-927. https://doi.org/10.1182/blood-2010-05-282921
Karjalainen, Katja ; Jaalouk, Diana E. ; Bueso-Ramos, Carlos E. ; Zurita, Amado J. ; Kuniyasu, Akihiko ; Eckhardt, Bedrich L. ; Marini, Frank C. ; Lichtiger, Benjamin ; O'Brien, Susan ; Kantarjian, Hagop M. ; Cortes, Jorge E. ; Koivunen, Erkki ; Arap, Wadih ; Pasqualini, Renata. / Targeting neuropilin-1 in human leukemia and lymphoma. In: Blood. 2011 ; Vol. 117, No. 3. pp. 920-927.
@article{7677b0a190a7412eb0d5577dc3093a04,
title = "Targeting neuropilin-1 in human leukemia and lymphoma",
abstract = "Targeted drug delivery offers an opportunity for the development of safer and more effective therapies for the treatment of cancer. In this study, we sought to identify short, cell-internalizing peptide ligands that could serve as directive agents for specific drug delivery in hematologic malignancies. By screening of human leukemia cells with a combinatorial phage display peptide library, we isolated a peptide motif, sequence Phe-Phe/Tyr-Any-Leu-Arg-Ser (FF/YXLRS), which bound to different leukemia cell lines and to patient-derived bone marrow samples. The motif was internalized through a receptor-mediated pathway, and we next identified the corresponding receptor as the transmembrane glycoprotein neuropilin-1 (NRP-1). Moreover, we observed a potent anti-leukemia cell effect when the targeting motif was synthesized in tandem to the pro-apoptotic sequence D(KLAKLAK)2. Finally, our results confirmed increased expression of NRP-1 in representative human leukemia and lymphoma cell lines and in a panel of bone marrow specimens obtained from patients with acute lymphoblastic leukemia or acute myelogenous leukemia compared with normal bone marrow. These results indicate that NRP-1 could potentially be used as a target for liganddirected therapy in human leukemias and lymphomas and that the prototype CGFYWLRSC-GG- D(KLAKLAK)2 is a promising drug candidate in this setting.",
author = "Katja Karjalainen and Jaalouk, {Diana E.} and Bueso-Ramos, {Carlos E.} and Zurita, {Amado J.} and Akihiko Kuniyasu and Eckhardt, {Bedrich L.} and Marini, {Frank C.} and Benjamin Lichtiger and Susan O'Brien and Kantarjian, {Hagop M.} and Cortes, {Jorge E.} and Erkki Koivunen and Wadih Arap and Renata Pasqualini",
year = "2011",
month = "1",
day = "20",
doi = "10.1182/blood-2010-05-282921",
language = "English (US)",
volume = "117",
pages = "920--927",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "3",

}

TY - JOUR

T1 - Targeting neuropilin-1 in human leukemia and lymphoma

AU - Karjalainen, Katja

AU - Jaalouk, Diana E.

AU - Bueso-Ramos, Carlos E.

AU - Zurita, Amado J.

AU - Kuniyasu, Akihiko

AU - Eckhardt, Bedrich L.

AU - Marini, Frank C.

AU - Lichtiger, Benjamin

AU - O'Brien, Susan

AU - Kantarjian, Hagop M.

AU - Cortes, Jorge E.

AU - Koivunen, Erkki

AU - Arap, Wadih

AU - Pasqualini, Renata

PY - 2011/1/20

Y1 - 2011/1/20

N2 - Targeted drug delivery offers an opportunity for the development of safer and more effective therapies for the treatment of cancer. In this study, we sought to identify short, cell-internalizing peptide ligands that could serve as directive agents for specific drug delivery in hematologic malignancies. By screening of human leukemia cells with a combinatorial phage display peptide library, we isolated a peptide motif, sequence Phe-Phe/Tyr-Any-Leu-Arg-Ser (FF/YXLRS), which bound to different leukemia cell lines and to patient-derived bone marrow samples. The motif was internalized through a receptor-mediated pathway, and we next identified the corresponding receptor as the transmembrane glycoprotein neuropilin-1 (NRP-1). Moreover, we observed a potent anti-leukemia cell effect when the targeting motif was synthesized in tandem to the pro-apoptotic sequence D(KLAKLAK)2. Finally, our results confirmed increased expression of NRP-1 in representative human leukemia and lymphoma cell lines and in a panel of bone marrow specimens obtained from patients with acute lymphoblastic leukemia or acute myelogenous leukemia compared with normal bone marrow. These results indicate that NRP-1 could potentially be used as a target for liganddirected therapy in human leukemias and lymphomas and that the prototype CGFYWLRSC-GG- D(KLAKLAK)2 is a promising drug candidate in this setting.

AB - Targeted drug delivery offers an opportunity for the development of safer and more effective therapies for the treatment of cancer. In this study, we sought to identify short, cell-internalizing peptide ligands that could serve as directive agents for specific drug delivery in hematologic malignancies. By screening of human leukemia cells with a combinatorial phage display peptide library, we isolated a peptide motif, sequence Phe-Phe/Tyr-Any-Leu-Arg-Ser (FF/YXLRS), which bound to different leukemia cell lines and to patient-derived bone marrow samples. The motif was internalized through a receptor-mediated pathway, and we next identified the corresponding receptor as the transmembrane glycoprotein neuropilin-1 (NRP-1). Moreover, we observed a potent anti-leukemia cell effect when the targeting motif was synthesized in tandem to the pro-apoptotic sequence D(KLAKLAK)2. Finally, our results confirmed increased expression of NRP-1 in representative human leukemia and lymphoma cell lines and in a panel of bone marrow specimens obtained from patients with acute lymphoblastic leukemia or acute myelogenous leukemia compared with normal bone marrow. These results indicate that NRP-1 could potentially be used as a target for liganddirected therapy in human leukemias and lymphomas and that the prototype CGFYWLRSC-GG- D(KLAKLAK)2 is a promising drug candidate in this setting.

UR - http://www.scopus.com/inward/record.url?scp=78751687553&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78751687553&partnerID=8YFLogxK

U2 - 10.1182/blood-2010-05-282921

DO - 10.1182/blood-2010-05-282921

M3 - Article

C2 - 21063027

AN - SCOPUS:78751687553

VL - 117

SP - 920

EP - 927

JO - Blood

JF - Blood

SN - 0006-4971

IS - 3

ER -